Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07356817

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.

The goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Cardiovascular diseases (CVD) are the leading cause of death among women, particularly non-obstructive myocardial infarction, heart failure, and stroke. However, neither women themselves nor, often, their physicians are fully aware of this reality. This lack of awareness is partly due to gender-related myths and biases that have led to insufficient study of the specific causes and risk factors that affect women's cardiovascular systems. Traditionally, it has been assumed that cardiovascular risk mechanisms, prediction, diagnosis, and treatment are the same in men and women. Today, it is known that this is not true: while the severity and mortality due to cardiovascular disease have decreased in men, they continue to rise and remain more severe among women.

Reproductive history and hormonal influence play a decisive role in modulating cardiovascular risk in women. Experiencing complications during pregnancy - such as preeclampsia (a hypertensive disorder caused by abnormal placental function), preterm delivery, or the birth of a low-weight infant - increases the risk of cardiovascular complications up to sevenfold later in life, compared with women who had normal pregnancies. This is explained by the fact that the cardiovascular system undergoes major adaptive changes during pregnancy; in complicated pregnancies, these adaptations fail to occur properly, resulting in cardiovascular stress and damage.

Among the objectives of this project, the investigators also aim to evaluate other risk factors such as lifestyle and external influences like exposure to environmental pollutants, which may further contribute to cardiovascular vulnerability. Pregnancy represents a critical window of susceptibility - as seen in other conditions such as COVID-19 - during which these environmental and biological impacts on the cardiovascular system are amplified.

In this project, the aim is to investigate how all these factors determine cardiovascular health in a cohort of 1,800 mothers, assessed 3 to 6 years after childbirth. The investigators will also examine how postnatal lifestyle and self-care behaviors may either mitigate or exacerbate this imprint. Women often prioritize their families' needs over their own, which can make it difficult to maintain healthy habits that reduce cardiovascular risk. Moreover, the investigators will study how environmental exposures influence maternal health and explore potential predictive and preventive strategies.

The goal is to develop an easy-to-use algorithm or test - ideally in the form of a mobile application - to help women and their physicians assess cardiovascular risk. Although predictive algorithms for cardiovascular health already exist, they have mostly been developed in predominantly male or older populations, and none have considered pregnancy-related factors or environmental exposures, both of which are key determinants of women's cardiovascular health.

To date, preventive cardiovascular strategies have not been specifically designed for women, and even less so for recently postpartum women. Existing tools have not been adapted for this population. This project brings together obstetricians and cardiologists, as well as midwives and primary care physicians - the healthcare professionals primarily responsible for women's health and well-being. The investigators believe that this multidisciplinary approach is crucial to anticipate cardiovascular disease and implement truly preventive strategies.

All study findings will be disseminated through educational sessions for healthcare professionals, new clinical tools and practices to improve patient satisfaction, audiovisual materials for better maternal health communication, and through professional societies (such as SEGO, SEC, SEAP, SEM, etc.). Results will also be published in open-access scientific journals and shared via public outreach, including media coverage, conferences in hospitals and community centers, social media (@DonaSantPau), and the institutional website (http://www.santpau.cat/web/public/go-inici

).

The active participation of women in this study will also allow the creation of discussion and advocacy groups among participants, supporting dissemination through social media, online platforms (https://inatal.org), and patient associations (such as El parto es nuestro), as well as newspapers, radio, and television.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1/PlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16/00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19/00702) cohort studies
  • Who have delivered within the previous 3-6 years.
  • Give written consent when invited to participate in this study protocol.

Exclusion criteria

  • Unwillingness to participate in this study
  • Probability of loss to follow-up.

Treatment and study plan

Primary outcomes

  1. Hypertension

    Time frame: 3-6 years after index pregnancy

    Presence of hypertension, defined as stage 1 hypertension (SBP of 130-139 or DBP of 80-89 mmHg)

  2. Abnormal cardiac function

    Time frame: 3-6 years after index pregnancy

    Abnormal cardiac function in the echocardiographic ultrasound assessment. Abnormal values of the different parameters will be considered according to reference limits published in 2020 by the British Society of Echocardiography

  3. Biochemical cardiac markers

    Time frame: 3-6 years after index pregnancy

    Abnormal biochemical cardiac markers: NTproBNP >300 ng/L or high-sensitivity troponin>30 ng/L

  4. Coronary artery disease

    Time frame: 3-6 years after index pregnancy

    Signs of coronary artery disease by computer tomography (CCT) myocardial perfusion imaging (mild (CACS≥10 AU and <100 AU); moderate (CACS≥100 AU and <400 AU) and severe (CACS ≥400 AU)

  5. Other cardiovascular major events

    Time frame: 3-6 years after index pregnancy

    Cardiovascular major events (ictus, coronary artery disease, cardiac insufficiency or myocardiopathy)

Secondary outcomes

  1. Age

    Time frame: 3-6 years after index pregnancy

    Patient age

  2. Pregnancy complications

    Time frame: 3-6 years after index pregnancy

    Preeclampsia, pregnancy complications, presence of fetal distress, perinatal mortality, neonatal morbidity, and neonatal mortality.

  3. Antrophometric measurements

    Time frame: 3-6 years after index pregnancy

    Percentages of body fat, muscle mass, visceral fat

  4. Blood pressure

    Time frame: 3-6 years after index pregnancy

    Systolic and Dyastolic blood pressure

  5. Computer tomography (CCT) myocardial perfusion imaging and RM Quantitative Myocardial Perfusion

    Time frame: 3-6 years after index pregnancy

    Allows an accurate and reliable assessment of both coronary epicardial stenosis and myocardial CT perfusion imaging at rest and during pharmacologic stress in the same examination. CCT will be performed with a 256-slice CT scanner (Philips Healthcare scanner) with prospective ECG-triggering as previously described. First, a noncontrast CCT will be performed to calculate the CACS using the Agatston scoring method. Second, CCTA will be performed following sublingual nitroglycerin and injection of nonionic contrast (Iopromide, Ultravist, Bayer Healthcare, Berlin, Germany). The presence of any coronary plaque (noncalcified, calcified, or mixed) and the presence of significant stenosis (≥50%) was assessed in all 17 coronary segments. One of 2 assigned and experienced cardiovascular radiologists assessed the CT scans for each participant.

  6. Cardiovascular markers in maternal blood

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected without anticoagulant to obtain serum. Troponin T and NTproBNP will be measured in ng/ml using automated electrochemiluminescence immunoassays on the Roche Cobas platform (Roche Diagnostics GmbH, Mannheim, Germany).Intra-and interassay coefficients of variation were found to be <5%.

  7. Laboratory data measured in mg/dl

    Time frame: 3-6 years after index pregnancy

    glucose, uric acid, creatinine, VLDL, LDL, HDL, total cholesterol, triglycerides

  8. Cardiovascular assessment according to IBERLIFERISK score

    Time frame: 3-6 years after index pregnancy

    A score >50% is considered as a high-risk for CVD.

  9. Hair sampling for cortisol determination

    Time frame: 3-6 years after index pregnancy

    Hair samples will be cut with scissors from the region of the posterior vertex, as close to the scalp as possible. Considering that hair grows approximately 1 cm per month, 3 cm will be obtained in order to evaluate hair cortisol levels representative of the last 3 months. Samples will be stored (in a dark container at room temperature) until analysis by liquid chromatography mass spectrometry.

  10. Diet and nutrition

    Time frame: 3-6 years after index pregnancy

    evaluated by means of the Short Diet Quality Screener by REGICOR (registre Gironí del Cor) and by means of the validated 14-item questionnaire of adherence to the Mediterranean diet. Escale from 1-31. The highest the score, the highest the adherence to the mediterranean diet.

  11. Physical activity

    Time frame: 3-6 years after index pregnancy

    evaluated by means of the Physical Activity Questionnaire by REGICOR, a validated questionnaire for quantifying physical activity in our population. The short questionnaire estimates energy expenditure in total PA and by intensity (light, moderate, vigorous), and includes 2 questions about sedentary behavior and a question about occupational PA.

  12. Stress

    Time frame: 3-6 years after index pregnancy

    evaluated by the Perceived Stress Scale (PSS) Questionnaire, validated for quantifying perceived stress in our population. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived this: Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress.

  13. Mental health

    Time frame: 3-6 years after index pregnancy

    evaluated by the Psychiatric Diagnostic Screening Questionnaire (PDSQ), a brief, psychometrically strong, self-report scale designed to screen for the most common disorders encountered in outpatient mental health settings and validated in our population. The final version of the questionnaire contains 13 subscales (major depressive disorder [MDD], bulimia, post-traumatic stress disorder [PTSD], panic disorder, agoraphobia, social phobia, generalized anxiety disorder [GAD], obsessive-compulsive disorder [OCD], alcohol abuse/dependence, drug abuse/dependence, somatization, hypochondriasis, and psychosis). Additionally, there is a six-item psychosis screen.

  14. Smoking habit

    Time frame: 3-6 years after index pregnancy

    evaluated by the Fagerström Questionnaire, validated questionnaire for quantifying dependence on smoking in our population.

  15. Women experiences and eHealth

    Time frame: 3-6 years after index pregnancy

    For this aim, a team of anthropologists with a long experience in the fields of health and reproduction will use qualitative methods to understand the needs of women with and without CV risk after pregnancy. To this end, semistructured interviews will be undertaken with patients with low and high risk of CV disease. These interviews will be useful to have a deep understanding of the difficulties, desires, and needs in relation to interactions with practitioners and available services in healthcare settings. For proactive monitoring and follow-up of patients, a technological platform or App (CardioPlan), currently used for cardiac rehabilitation, will be restructured, which has a highly secure data repository located on the provider's server and then validated in a subgroup of patients (n=100).

  16. BMI

    Time frame: 3-6 years after index pregnancy

    Weight and height will be combined to report BMI in kg/m^2

  17. Waist/Hip ratio

    Time frame: 3-6 years after index pregnancy

    Measurements in cm2 of waist and hip to calculate waist/hip ratio in cm2

  18. Heart rate

    Time frame: 3-6 years after index pregnancy

    Measured in hpm

  19. Echocardiographic assesment

    Time frame: 3-6 years after index pregnancy

    Performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High-resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis.

  20. Myocardial deformation (strain)

    Time frame: 3-6 years after index pregnancy

    measured by echocardiography is increasingly recognized as a more effective technique than conventional ejection fraction (EF) in detecting subtle changes in left ventricular (LV) function and in predicting outcomes. AutoStrain TOMTEC Philips EPIQ CVx ultrasound systemwould be used for the analysis.

  21. Carotid intima-media thickness

    Time frame: 3-6 years after index pregnancy

    Transverse longitudinal evaluation of the common carotid artery, its bifurcation and internal carotid artery. Thickness of the intima layer is measured at the middle third of the common carotid artery and is considered the measurement between the tunica intima and tunica media, the innermost two layers of the wall of an artery.

  22. ophthalmic artery evaluation

    Time frame: 3-6 years after index pregnancy

    The woman is placed in a supine position to rest for 5 minutes. A 7.5-MHz linear transducer is then placed transversely and gently over her closed upper eyelid after application of conduction gel. Color flow Doppler is used to identify the ophthalmic artery, which is found superior and medially to the hypoechoic band representing the optic nerve. Pulsed-wave Doppler is then used to record 3 to 5 similar waveforms. Doppler studies are performed twice in each eye, and the average of the 4 measurements is used for analysis.

  23. Cardiovascular markers in maternal blood

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected without anticoagulant to obtain serum. Placental growth factor (PlGF) will be measured in pg/ml using automated electrochemiluminescence immunoassays on the Roche Cobas platform (Roche Diagnostics GmbH, Mannheim, Germany).Intra-and interassay coefficients of variation were found to be <5%.

  24. Laboratory data measured in g/l

    Time frame: 3-6 years after index pregnancy

    Venous blood samples and urine samples will be collected to measure hemoglobin and protein in urine

  25. Laboratory data measured in l/l

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure hematocrit

  26. Laboratory data measured in U/mcl

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure leukocytes and platalets

  27. Laboratory data measured in mmol/l

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure potassium and sodium

  28. Laboratory data measured in %

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure glicated hemoglobin

  29. Laboratory data measured in U/L

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure alanine transaminases, aspartate aminotransferases and lactate dehydrogenase

  30. Laboratory data measured in mg/l

    Time frame: 3-6 years after index pregnancy

    Urine samples will be collected to measure albumin

  31. Laboratory data measured in mUI/l

    Time frame: 3-6 years after index pregnancy

    Venous blood samples will be collected to measure tirotropin and prolactin

  32. Ethnicity

    Time frame: 3-6 years after index pregnancy

    Patient ethnicity

  33. Smoking status

    Time frame: 3-6 years after index pregnancy

    Patient smoking status

  34. Menstrual type

    Time frame: 3-6 years after index pregnancy

    Patient menstrual type and presence of menopause

  35. Diseases

    Time frame: 3-6 years after index pregnancy

    Diabetes, obesity, and other maternal diseases associated with cardiovascular risk

  36. Interval from index preganancy

    Time frame: 3-6 years after index pregnancy

    interval in years from index pregnancy.

  37. Gestational age at delivery

    Time frame: 3-6 years after index pregnancy

    Gestational age at delivery in index pregnancy

  38. Mode of delivery

    Time frame: 3-6 years after index pregnancy

    mode of delivery at index pregnancy,

  39. Labor induction

    Time frame: 3-6 years after index pregnancy

    labor induction at index pregnancy

  40. Child's gender

    Time frame: 3-6 years after index pregnancy

    Child's gender in index pregnancy

  41. Birth weight percentile

    Time frame: 3-6 years after index pregnancy

    birth weight percentile in index pregnancy

  42. Birth weight

    Time frame: 3-6 years after index pregnancy

    Child's birth weight at index pregancy.

  43. APGAR score

    Time frame: 3-6 years after index pregnancy

    5-minute Apgar score in index pregnancy. Apgar score measures appareance, pulse, grimance, acivity and respiratory effort. For each chriteria newborns can receive a punctuation from 0 to 2, qhere 2 is the better punctuation.

  44. Blood preassure during pregnancy

    Time frame: 3-6 years after index pregnancy

    Blood preassure druing index pregnancy

  45. Weight during pregnancy

    Time frame: 3-6 years after index pregnancy

    Weight during index pregnancy.

Study contacts

Contact information is provided by the study sponsor or research team.

Elisa Llurba Olivé, PhD

CONTACT

[email protected]

+34 935534078

Pablo García Manau, PhD

CONTACT

[email protected]

+34 627813346

Sponsors and collaborators

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Other

Collaborators

  • Barcelona Institute for Global Health
  • Hospital Sant Joan de Deu

Registry information

Acronym: CARDIOMOM

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jan 21, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.